[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354165-105":59,"doc-detail-354165-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anabolics-in-cancer-patients-to-use-or-not-to-use-review-article","Anabolics in Cancer Patients: To Use or Not to Use - Review Article","","Cancer survival rates have improved, making long-term management of cancer treatment-induced bone loss and osteoporosis increasingly important for cancer survivors. This review addresses whether anabolic agents should be used in cancer patients, focusing on parathyroid hormone receptor agonists and romosozumab. It summarizes preclinical and clinical evidence, outlines key safety concerns and current guideline cautions, and discusses patient selection based on fracture risk versus potential oncologic safety risks.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anabolics-in-cancer-patients-to-use-or-not-to-use-review-article/354165/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anabolics-in-cancer-patients-to-use-or-not-to-use-review-article/354165.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":8},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which anabolic agents are discussed for cancer patients?","Question",{"text":112,"@type":113},"The review focuses on parathyroid hormone (PTH) receptor agonists such as teriparatide and abaloparatide, and the anti-sclerostin antibody romosozumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is anabolic therapy limited in cancer patients despite its effectiveness?",{"text":117,"@type":113},"Its use is constrained by safety concerns and insufficient clinical evidence in this population, leading to conservative approaches in guidelines.",{"name":119,"@type":110,"acceptedAnswer":120},"How should anabolic treatment be considered when managing osteoporosis in cancer survivors?",{"text":121,"@type":113},"The decision should be individualized, carefully balancing the patient’s fracture risk with potential oncologic safety concerns, and may be considered cautiously for selected survivors with an adequate disease-free interval depending on recurrence risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354165,1790142620,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":8,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Review Article  \nEndocrinol Metab 2026;41:222-230 [https://doi.org/10.3803/EnM.2026.3027](https://doi.org/10.3803/EnM.2026.3027)[ ](https://doi.org/10.3803/EnM.2026.3027)[pISSN 2093-596X](pISSN 2093-596X) · eISSN 2093-5978  \nAnabolics in Cancer Patients: To Use or Not to Use?  \nARam Hong  \nDivision of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea  \nWith improving cancer survival, the management of osteoporosis in cancer survivors has become increasingly important. Cancer treatment-induced bone loss and aging place many survivors at high risk of fragility fractures. Anabolic agents, including parathyroid hormone (PTH) receptor agonists and the anti-sclerostin antibody romosozumab, effectively stimulate bone formation and reduce fracture risk in the general population. However, their use in cancer patients remains limited because of safety concerns and insufficient clinical evidence. Preclinical studies suggested a potential risk of osteosarcoma with PTH analogues and possible effects on tumor growth or bone metastasis through modulation of the bone microenvironment, although long-term human studies have not demonstrated an increased malignancy risk. In clinical practice, PTH analogues are generally avoided in patients with active malignancy, bone metastases, hypercalcemia, or a history of osteosarcoma. In selected cancer survivors with a sufficiently long diseasefree interval, their cautious use may be considered depending on recurrence risk. Romosozumab may represent another potential option, although supporting evidence remains limited. Overall, the use of anabolic therapy in cancer patients should be individualized, carefully balancing fracture risk against potential oncologic safety concerns.  \n\n| Keywords: Anabolic therapy; Osteoporosis; Neoplasms; Bone metastasis; Fracture |  |\n| --- | --- |\n| INTRODUCTION\u003Cbr>Cancer survival rates have markedly improved worldwide owing to advances in early diagnosis, rapid progress in treatment modalities, and improved access to multidisciplinary cancer care. The definition of a ‘cancer survivor’ remains complex and controversial, ranging from individuals from the time of diagnosis throughout their lifetime to those who have completed curative-intent treatment (e.g., ≥5 years post-treatment) [1]. As survivorship improves, there is an increasing need to manage longterm adverse effects of cancer therapy and chronic comorbidities, including bone health. Cancer treatment-induced bone loss (CTIBL) refers to rapid and severe bone loss associated with | anticancer therapies [2], most commonly in breast and prostate cancers [3] . Moreover, because cancer predominantly affects older individuals, survivors are particularly vulnerable to osteoporosis and fragility fractures, which are associated with increased risks of hospitalization and mortality [4,5] .\u003Cbr>Osteoporosis is a systemic skeletal disorder characterized by low bone mass and structural deterioration, resulting in increased fracture susceptibility [6] . Anti-osteoporosis therapies are broadly classified into antiresorptive and anabolic agents based on their mechanisms of action. Antiresorptive agents inhibit osteoclast activity, thereby reducing bone remodeling and increasing bone mineral density (BMD) [7] . Current clinical guidelines recommend antiresorptive therapies, such as bisphos- |\n| Received: 15 March 2026, Revised: 27 March 2026, Accepted: 30 March 2026\u003Cbr>Corresponding author: ARam Hong\u003Cbr>Department of Internal Medicine, Chonnam National University Medical\u003Cbr>School, 160 Baekseo-ro, Dong-gu, Gwangju 61469, Korea\u003Cbr>Tel: +82-61-379-7822, Fax: +82-61-379-7628, [E-mail:](E-mail: wanilove23@nate.com)[ wanilove23@nate.com](E-mail: wanilove23@nate.com) | Copyright © 2026 Korean Endocrine Society\u003Cbr>This is an Open Access article distributed under the terms of\u003Cbr>the Creative Commons Attribution Non-Commercial License ([https://creativecommons.org/licenses/b","cbCail9YTSkPOQXC","https://ap.wps.com/l/cbCail9YTSkPOQXC","pdf",401972,"English","# Introduction\n# Proven Efficacy of Anabolic Therapy for Osteoporosis in General Population\n# Safety Concerns and Limitations in Cancer Patients\n# Clinical Evidence and Practical Considerations","[{\"question\":\"Which anabolic agents are discussed for cancer patients?\",\"answer\":\"The review focuses on parathyroid hormone (PTH) receptor agonists such as teriparatide and abaloparatide, and the anti-sclerostin antibody romosozumab.\"},{\"question\":\"Why is anabolic therapy limited in cancer patients despite its effectiveness?\",\"answer\":\"Its use is constrained by safety concerns and insufficient clinical evidence in this population, leading to conservative approaches in guidelines.\"},{\"question\":\"How should anabolic treatment be considered when managing osteoporosis in cancer survivors?\",\"answer\":\"The decision should be individualized, carefully balancing the patient’s fracture risk with potential oncologic safety concerns, and may be considered cautiously for selected survivors with an adequate disease-free interval depending on recurrence risk.\"}]","Anabolics in Cancer Patients: To Use or Not to Use - Review Article | PDF",1790109310,23]